Search Results - "Spicka I"

Design of sludge digestion tanks.

Authors: s̮pic̮ka, I.

Source: Proceedings of the American Society of Civil Engineers; August 1969, Vol. 95, p795-798, 4p

Micro Operation System for Microprocessor Applications.

Authors: Krejcar, O. Spicka, I. Frischer, R.

Source: Electronics & Electrical Engineering; 2011, Issue 114, p83-88, 6p

Implementation of Full-Featured PID Regulator in Microcontrollers.

Authors: Krejcar, O. Spicka, I. Frischer, R.

Source: Electronics & Electrical Engineering; 2011, Issue 113, p77-82, 6p

Fluctuation of effluent quality from activated sludge plants.

Authors: S̮pic̮ka, I.

Source: Water Research; January 1968, Vol. 2, p52-53, 2p

Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.

Authors: Dimopoulos, M. A. Voorhees, P. M. Schjesvold, F. et al.

Source: New England Journal of Medicine. 5/8/2025, Vol. 392 Issue 18, p1777-1788. 12p.

Prehoz pres zada.

Authors: Novak, J. Spicka, I.

Source: Teorie a Praxe Telesne Vychovy. 1980: Vol. 28 Issue 10. p. 622-630-630.

Fundamental principles of falling down.

Authors: Novak, J. Spicka, I.

Source: Teorie a Praxe Telesne Vychovy. 1979: Vol. 27 Issue 2. p. 102-106-106.

Principy porazu - chvaty druheho archetypu.

Authors: Novak, J. Spicka, I.

Source: Teorie a Praxe Telesne Vychovy. 1981: Vol. 29 Issue 10. p. 625-630-630.

Continuous lenalidomide treatment for newly diagnosed multiple myeloma.

Authors: Palumbo A Hajek R Delforge M et al.

Source: New England Journal of Medicine. 5/10/2012, Vol. 366 Issue 19, p1759-1769. 11p.

Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma.

Authors: San Miguel JF Schlag R Khuageva NK et al.

Source: New England Journal of Medicine. 8/28/2008, Vol. 359 Issue 9, p906-917. 12p.

URL: 34059650

BRIDGE (OP-107): A Phase 2 Pharmacokinetic Study of Melflufen Plus Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Impaired Renal Function.

Authors: Pour L Delimpasi S Legiec W et al.

Source: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2026 Jul; Vol. 26 (7), pp. e942-e952. Date of Electronic Publication: 2026 Apr 30.

Publication Type: Journal Article; Clinical Trial, Phase II; Multicenter Study

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101525386 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2152-2669 (Electronic) Linking ISSN: 21522669 NLM ISO Abbreviation: Clin Lymphoma Myeloma Leuk Subsets: MEDLINE

Outcomes of CAR-T Cell Therapy and Bispecific Antibodies as Single-Modality and Sequential Strategies in Relapsed/Refractory Multiple Myeloma.

Authors: Merz M Jelinek T Pabst T et al.

Source: Blood cancer discovery [Blood Cancer Discov] 2026 Jun 12. Date of Electronic Publication: 2026 Jun 12.

Publication Type: Journal Article

Journal Info: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 101764786 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2643-3249 (Electronic) Linking ISSN: 26433230 NLM ISO Abbreviation: Blood Cancer Discov Subsets: MEDLINE

De-escalated Teclistamab dosing in relapsed/refractory multiple myeloma: Czech myeloma group real-world evidence analysis.

Authors: Stork M Radocha J Mihalyova J et al.

Source: Annals of hematology [Ann Hematol] 2025 Aug; Vol. 104 (8), pp. 4141-4147. Date of Electronic Publication: 2025 Aug 18.

Publication Type: Journal Article; Multicenter Study

Journal Info: Publisher: Springer Verlag Country of Publication: Germany NLM ID: 9107334 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1432-0584 (Electronic) Linking ISSN: 09395555 NLM ISO Abbreviation: Ann Hematol Subsets: MEDLINE

Final Results of a Phase 2 Multi-Arm Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma.

Authors: Paul B Minarik J Cottini F et al.

Source: EJHaem [EJHaem] 2025 Jun 06; Vol. 6 (3), pp. e70072. Date of Electronic Publication: 2025 Jun 06 (Print Publication: 2025).

Publication Type: Journal Article

Journal Info: Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101761942 Publication Model: eCollection Cited Medium: Internet ISSN: 2688-6146 (Electronic) Linking ISSN: 26886146 NLM ISO Abbreviation: EJHaem Subsets: PubMed not MEDLINE

Treatment Patterns and Outcomes in Over 2200 Newly Diagnosed Multiple Myeloma Patients: Supporting Bortezomib-Lenalidomide-Dexamethasone as a Preferred Regimen in the Absence of Anti-CD38 Antibodies.

Authors: Jungova A Stork M Spicka I et al.

Source: Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2026 Apr; Vol. 26 (4), pp. e470-e482. Date of Electronic Publication: 2025 Nov 02.

Publication Type: Journal Article

Journal Info: Publisher: Elsevier Country of Publication: United States NLM ID: 101525386 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2152-2669 (Electronic) Linking ISSN: 21522669 NLM ISO Abbreviation: Clin Lymphoma Myeloma Leuk Subsets: MEDLINE

Lenalidomide based triplets in relapsed/refractory multiple myeloma: analysis of the Czech Myeloma Group.

Authors: Minarik J Pour L Latal V et al.

Source: BMC cancer [BMC Cancer] 2025 Apr 09; Vol. 25 (1), pp. 651. Date of Electronic Publication: 2025 Apr 09.

Publication Type: Journal Article

Journal Info: Publisher: BioMed Central Country of Publication: England NLM ID: 100967800 Publication Model: Electronic Cited Medium: Internet ISSN: 1471-2407 (Electronic) Linking ISSN: 14712407 NLM ISO Abbreviation: BMC Cancer Subsets: MEDLINE

Allocation and validation of the second revision of the International Staging System in the ICARIA-MM and IKEMA studies.

Authors: Richardson PG Perrot A Mikhael J et al.

Source: Blood cancer journal [Blood Cancer J] 2024 Nov 28; Vol. 14 (1), pp. 209. Date of Electronic Publication: 2024 Nov 28.

Publication Type: Journal Article; Clinical Trial, Phase III; Validation Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

Journal Info: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE

An open-label, first-in-human, single agent, dose escalation study for the evaluation of safety and efficacy of SAR442085 in patients with relapsed or refractory multiple myeloma.

Authors: Kapoor P Nathwani N Jelinek T et al.

Source: European journal of haematology [Eur J Haematol] 2024 Nov; Vol. 113 (5), pp. 593-605. Date of Electronic Publication: 2024 Jul 12.

Publication Type: Journal Article; Multicenter Study; Clinical Trial, Phase I

Journal Info: Publisher: Blackwell Country of Publication: England NLM ID: 8703985 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1600-0609 (Electronic) Linking ISSN: 09024441 NLM ISO Abbreviation: Eur J Haematol Subsets: MEDLINE

Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials.

Authors: Mateos MV Trudel S Quach H et al.

Source: Blood advances [Blood Adv] 2025 Nov 25; Vol. 9 (22), pp. 5708-5719.

Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial

Journal Info: Publisher: American Society of Hematology Country of Publication: United States NLM ID: 101698425 Publication Model: Print Cited Medium: Internet ISSN: 2473-9537 (Electronic) Linking ISSN: 24739529 NLM ISO Abbreviation: Blood Adv Subsets: MEDLINE

Patient-reported outcomes with belantamab mafodotin, pomalidomide, and dexamethasone versus bortezomib, pomalidomide, and dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-8): a phase 3, open-label, randomised controlled trial.

Authors: Dimopoulos MA Beksac M Pour L et al.

Corporate Authors: Dimopoulos MA Beksac M Pour L et al.

Source: The Lancet. Haematology [Lancet Haematol] 2025 Nov; Vol. 12 (11), pp. e876-e886.

Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase III; Multicenter Study; Comparative Study

Journal Info: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101643584 Publication Model: Print Cited Medium: Internet ISSN: 2352-3026 (Electronic) Linking ISSN: 23523026 NLM ISO Abbreviation: Lancet Haematol Subsets: MEDLINE